Vasculitis & polymyalgia rheumatica
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
Authors' conclusion
The results of this SLR demonstrate that definitions of response used in clinical studies of GCA are scant and heterogeneous. RCTs and LOS mainly used remission and relapse as treatment outcomes.
Study context
- Population
- Randomised controlled trials (RCTs), longitudinal observational studies (LOS) with >20 subjects and qualitative research studies on response to treatment and change in disease activity in giant cell arteritis (GCA)11 RCTs, 104 LOS, 1 qualitative study
- Participants
- 116 participants
- Outcome
- Criteria and descriptors used to measure response to treatment and change in disease activity in GCA
Main finding
As reported in the abstract
Active disease described in LOS
19%
Remission reported in RCTs; predominantly defined as combination of clinical and laboratory components
73%
Remission reported in LOS
42%
Relapse reported in LOS
86%
Original publication
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force. RMD Open. Published 22 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →